For months, one of the most common criticisms leveled against Robert F. Kennedy Jr. has been that he is skeptical of government public health authority.

During the COVID-19 pandemic, Kennedy repeatedly criticized lockdowns, vaccine mandates, and government restrictions on personal liberty. Many of his supporters viewed him as a defender of individual rights against government overreach.

Which is why this week’s news is so remarkable.

According to multiple reports, HHS Secretary Robert F. Kennedy Jr. personally overruled federal medical reviewers and signed an order requiring a Florida woman exposed to Andes hantavirus aboard the MV Hondius cruise ship to remain in federal quarantine in Nebraska against her wishes.

The woman, Angela Perryman, has remained symptom-free for more than five weeks. A CDC-led medical review reportedly concluded that she could safely complete monitoring from her home in Florida. Nevertheless, Kennedy issued an order requiring her continued confinement until the end of the 42-day monitoring period.

This is not merely a story about one passenger.

It is a story about public health powers, political consistency, and what happens when theoretical debates become real-world decisions.

Why Was She Quarantined?

The outbreak aboard the expedition cruise ship MV Hondius has been unlike anything we’ve seen in recent years.

The outbreak involved the Andes virus, a strain of hantavirus that is unusual because it is one of the few hantaviruses known to spread from person to person under certain circumstances. Three deaths were linked to the outbreak, and multiple passengers became infected. As a result, exposed passengers were placed under a 42-day monitoring period after returning to their home countries.

Most public health experts have emphasized that Andes virus is not remotely comparable to COVID-19. Transmission generally requires prolonged close contact, and the overall risk to the public remains low.

Still, because the incubation period can be exceptionally long, exposed travelers were placed under quarantine or active monitoring.

The Public Health Question

As a physician, I think it is important to separate two different questions.

The first is scientific:

Can governments ever justify quarantining someone exposed to a dangerous infectious disease?

The answer is yes.

Quarantine authority has existed for centuries because there are situations in which temporary restrictions on movement may be necessary to protect the public.

The second question is much harder:

When is that authority justified, and who gets to decide?

That is where this case becomes fascinating.

Reports indicate that CDC experts believed Perryman could safely complete monitoring at home. Kennedy disagreed and exercised his authority as HHS Secretary to keep her in a federal facility.

Whether one agrees with the decision or not, it represents a striking example of political leadership overriding the recommendations of career public health officials.

The Irony

There is an irony here that should not be ignored. Many Americans who opposed COVID-era restrictions argued that public health authorities were too willing to limit individual liberties.

Now, some of those same voices are defending a quarantine order that federal medical reviewers reportedly did not believe was necessary. Meanwhile, some former defenders of aggressive COVID interventions are criticizing the government’s decision.

This does not automatically mean the quarantine order is wrong. It does mean that our views on public health powers should be consistent regardless of who occupies the office.

If we believe experts should guide policy, that principle should apply when we agree with the experts and when we do not.

If we believe elected officials should have broad authority to override experts, that principle should also apply consistently.

Personally? I do not believe that RFK Jr. is qualified to make these decisions, which makes this situation even more complicated.

What Happens Next?

The 42-day monitoring period is scheduled to end on June 21. Federal officials have indicated that remaining quarantined passengers are expected to leave shortly thereafter.

From a medical standpoint, the likelihood that an asymptomatic passenger suddenly develops disease decreases with each passing day. From a policy standpoint, however, this case may have a longer shelf life.

Future debates about quarantine authority, infectious disease response, and the balance between individual liberty and public safety will likely point back to this decision.

Because regardless of your political views, this week provided a reminder of something important:

Public health powers are neither inherently good nor inherently bad.

What matters is how they are used, whether they are evidence-based, and whether we apply the same standards no matter who is in charge. That’s a lesson worth remembering long after this quarantine ends.

Share

Although not required, any support is greatly appreciated, including purchasing my new book.

Yesterday, a controversy erupted at one of the world’s largest diabetes conferences that raises important questions about science, advocacy, and the boundaries of professional discourse.

At the American Diabetes Association’s Scientific Sessions in New Orleans, several diabetes researchers, including the editor-in-chief of Diabetes Care, one of the field’s leading journals, were forcibly removed from the conference after distributing copies of a recently published editorial titled “Misguided Brushes of a Pen Continue to Dismantle American Diabetes Research.” The editorial criticized recent federal actions affecting biomedical research funding and infrastructure. Original reporting came from MedPage Today.

The story quickly spread across scientific circles and social media. Some viewed the incident as an attempt to silence researchers, while others argued that conference organizers were simply enforcing existing policies. The reality may be more complicated than either characterization suggests.

Before discussing what happened, it is important to acknowledge that the ADA does have a code of conduct governing behavior at its meetings. The policy prohibits “disorderly or disruptive conduct such as protesting” and gives conference leadership the authority to remove attendees who violate conference rules. In that sense, the central question is not whether the ADA had the authority to act. Rather, it is whether distributing a published editorial about research funding should be considered a protest in the first place.

Reasonable people can disagree on that answer. Yet it is a question worth examining because scientific conferences exist specifically to facilitate discussion, debate, and sometimes disagreement. Researchers routinely challenge one another’s conclusions, debate study designs and statistical methods, and argue over clinical guidelines and interpretations of evidence. Scientific progress depends on those exchanges.

What makes this situation unusual is that the topic being debated was not a drug, a laboratory finding, or a clinical trial. It was the future of scientific research itself.

The editorial at the center of the controversy was not primarily about partisan politics. Instead, it focused on the practical consequences of federal policy decisions on diabetes research. The authors argued that a series of executive actions and administrative decisions have weakened the scientific infrastructure that has fueled decades of progress in diabetes prevention, treatment, and technology.

They pointed to disruptions in National Institutes of Health funding, reductions in research support, uncertainty surrounding grant review processes, and broader concerns about the stability of the biomedical research enterprise. According to the authors, these developments threaten the pipeline of discoveries that ultimately translate into better care for people living with diabetes.

The editorial also highlighted something many outside the scientific community may not fully appreciate: advances in diabetes care do not happen spontaneously. Continuous glucose monitors, automated insulin delivery systems, GLP-1 receptor agonists, and therapies that reduce kidney disease, cardiovascular complications, blindness, and amputations all emerged from years (often decades) of federally supported scientific research. The editorial’s central argument was that weakening the nation’s research infrastructure today risks slowing the discoveries of tomorrow.

Whether one agrees with that assessment or not, it is fundamentally an argument about science policy and its consequences for patients. For scientists working in diabetes research, these concerns are not abstract political talking points. Research funding is the foundation upon which scientific progress is built. Every new insulin formulation, every improvement in glucose monitoring technology, every advance in insulin pump systems, and every breakthrough medication that improves quality of life begins with research, and research requires sustained investment.

This is why many researchers reacted so strongly to reports that scientists were removed from a scientific meeting while discussing policies affecting science itself.

Part of that reaction stems not only from the decision to remove the researchers, but also from how the removal reportedly occurred. According to contemporaneous reporting, conference security and local law enforcement officers were involved, and some researchers were forcibly escorted out after refusing requests to stop distributing the editorial. MedPage Today published video footage of the incident here.

Many attendees viewed that level of enforcement as unusual. Professional societies certainly have the right to enforce conference rules, and if organizers determine that attendees are violating a code of conduct, they can ask them to stop or leave. However, the involvement of police officers at a scientific meeting—particularly in response to the distribution of a published editorial—struck many observers as disproportionate to the circumstances.

Reasonable people may disagree about whether the researchers violated conference policy. Nevertheless, it is understandable why some scientists found the optics troubling. When police become involved in removing respected researchers from a scientific conference, the incident inevitably takes on a different character than a routine enforcement of meeting rules. For many observers, the image of scientists being escorted out by law enforcement raised concerns about whether the response matched the alleged offense.

At the same time, conference organizers have legitimate responsibilities. Large professional meetings establish rules to ensure safety, maintain order, and prevent disruptions that interfere with educational programming. Those rules exist for good reason.

The challenge lies in determining where scientific advocacy ends and political protest begins. Is distributing a peer-reviewed editorial about research funding a form of scientific discourse? Is it advocacy? Is it protest? The answer may depend on who you ask, but the distinction matters.

If discussions about threats to scientific research are categorized as protest activity, many scientists worry that conversations about the future of their field could become increasingly difficult to have at the very meetings where they are most relevant. Scientific conferences have traditionally served as forums not only for presenting data but also for discussing the broader conditions that make scientific discovery possible.

As a physician, I do not expect everyone to agree about government spending priorities, agency leadership, or how research dollars should be allocated. Those are legitimate subjects for debate in a democratic society. However, I do believe scientific communities should be able to openly discuss policies that directly affect scientific discovery.

That does not mean every conference should become a political rally. It does mean that medical and scientific societies must carefully consider where they draw the line between disruptive activism and legitimate discussion about issues that affect research, patient care, and public health.

The controversy at the ADA meeting is ultimately bigger than diabetes. It raises broader questions about how scientific organizations navigate increasingly polarized political environments and how they balance institutional neutrality with advocacy for the scientific enterprise itself.

How should professional societies respond when government policies directly affect the ability of scientists to conduct research? How should they distinguish between political activism and discussion of science policy? And perhaps, most importantly, where should those conversations take place if not among scientists themselves?

Science does not require unanimity. It requires evidence, debate, and the willingness to engage with difficult questions. Sometimes, it also requires the freedom to discuss uncomfortable realities, even when the answers are complicated.

Share

Although not required, any support is greatly appreciated, including purchasing my new book.

When Secretary Robert F. Kennedy Jr. celebrated “500 historic days” alongside President Trump, the accompanying graphic caught my attention.

Not because of the policy claims, but because it was a parody of (500) Days of Summer.

For those unfamiliar with the film, (500) Days of Summer is not a movie about leadership, public service, scientific achievement, or public health. It’s a romantic comedy-drama about an idealized relationship, misplaced expectations, and the gap between perception and reality, which makes it an oddly fitting metaphor.

Because the last 500 days have often felt less like an evidence-based public health agenda and more like a story driven by emotion, personality, and narrative.

Public health should not be a romance. It should not depend on charisma, celebrity, or personal loyalty. It should depend on evidence.

As a physician, I agree that chronic disease deserves more attention. Prevention matters. Nutrition matters. Exercise matters. Environmental health matters.

However, slogans are not science, and aesthetic branding is not evidence. Public trust is not built through viral social media posts or movie-poster-style tributes to political leaders. It is built through transparency, data, accountability, and a willingness to change course when the evidence demands it.

So rather than celebrating 500 days, let’s take an honest look at what those 500 days have actually meant for American science and public health.

Reason #1: Undermining Confidence in Vaccines

For decades, Kennedy promoted the false narrative that vaccines cause autism despite overwhelming evidence showing they do not.

Hundreds of studies involving millions of children from multiple countries have come up with the same conclusion. Yet, the myth persists because influential figures continue to give it oxygen.

The consequences are not theoretical. Declining vaccination rates lead to outbreaks of preventable diseases. We’ve already seen measles return to communities where vaccination coverage has fallen.

Reason #2: Reopening Settled Scientific Questions

Science is never truly settled in the philosophical sense. New evidence can always emerge, but not every question deserves equal attention forever.

The question of whether vaccines cause autism has been studied exhaustively. Continuing to frame it as an open controversy misleads the public about the actual state of the evidence.

Reason #3: Elevating Anecdotes Above Data

A compelling story can be emotionally powerful.

A dataset can be boring.

Unfortunately, reality doesn’t care which is more emotionally satisfying. Public health decisions should be guided by the weight of evidence, not by whichever anecdote generates the strongest reaction online.

Reason #4: Damaging Trust in Scientific Institutions

Scientific institutions are imperfect. They make mistakes and should be criticized when warranted. However, systematically portraying researchers, physicians, public health agencies, and scientific journals as fundamentally corrupt creates a vacuum that misinformation eagerly fills.

Reason #5: Turning Public Health Into a Culture War

Viruses don’t vote.

Cancer doesn’t care about political affiliation.

Neither does diabetes.

Public health succeeds when recommendations are based on evidence rather than ideology. The more health becomes a partisan identity marker, the harder it becomes to protect the public.

The Irony of the Poster

The more I looked at the (500) Days of Trump graphic, the more it seemed to capture the central problem.

Science isn’t supposed to be about personalities.

It’s not supposed to be about heroes and villains.

It’s not supposed to be about loyalty.

The scientific method doesn’t care who you are.

It only cares whether you’re right.

That’s why public health victories aren’t usually celebrated with movie posters.

They’re celebrated with fewer children in hospitals lower mortality rates, longer life expectancy, safer communities, and better health outcomes.

Those are the metrics that matter.

Not likes, retweets, slogans or celebrity.

And certainly not romantic-comedy-inspired political fan art.

The tragedy isn’t that Robert F. Kennedy Jr. asks questions. Science thrives on questions. The tragedy is that after 500 days in power, he still appears more interested in questioning the evidence than following it where it leads.

Share

Although not required, any support is greatly appreciated, including purchasing a copy of my new book.

A recent report that the Trump administration is exploring the use of facilities in Kenya to quarantine or treat Americans exposed to Ebola has sparked predictable reactions online.

Some people see it as proactive containment while others see it as fear-driven politics. However, beneath the politics is a much more uncomfortable ethical question:

Historically, the United States has done exactly that. During prior Ebola outbreaks, Americans infected overseas were transported back to highly specialized biocontainment units in places like the University of Nebraska and Emory University in Atlanta, Georgia. The process was extraordinarily controlled. Patients traveled in sealed isolation systems aboard specially equipped aircraft. The hospitals receiving them had teams specifically trained for diseases exactly like this. Despite widespread public fear at the time, those efforts did not trigger community spread in the United States.

That history matters because Ebola occupies a unique place in the public imagination. Few viruses generate as much visceral fear because of the high mortality rates and the visual protective suits. It becomes frightening to think that there could be an invisible, deadly pathogen crossing borders, but fear and actual transmission risk are not always the same thing.

Ebola is not COVID-19 or measles. It is not an airborne virus that spreads casually through a grocery store or airplane cabin. Ebola generally requires direct contact with bodily fluids from a symptomatic infected person. That makes it serious, but fundamentally different from respiratory pandemics, and that distinction matters when discussing whether infected Americans should be treated abroad or repatriated home. Because if the United States possesses some of the most advanced infectious disease containment facilities in the world, why would it avoid using them?

There are legitimate operational arguments. Transporting critically ill patients across continents is complicated and resource intensive. Regional treatment may reduce logistical strain. If larger outbreaks emerge, public health officials may want to preserve domestic capacity or minimize transport-associated risks.

Those are reasonable discussions to have, but there is also another possibility people are quietly thinking about:

• What if this decision is not primarily about medical safety?

• What if it is about public perception?

That is where the ethical tension becomes harder to ignore. If the wealthiest country in the world chooses not to bring home its own infected citizens, not because it cannot but because the optics are politically uncomfortable, that sends a message.

And people notice messages like that.

Public trust in health institutions has already been severely damaged over the last several years. One reason is that many Americans increasingly feel that decisions are being filtered through political calculations rather than explained transparently.

That erosion of trust has consequences. When leaders avoid nuance because nuance is politically inconvenient, fear fills the vacuum. The irony is that transparent communication is probably the strongest tool public health has. The public can handle complexity better than many officials assume.

You can simultaneously say:

• Ebola is a serious disease.

• Aggressive containment matters.

• Specialized transport is highly controlled.

• America has safely treated Ebola patients before.

• And repatriation can still be ethically justified.

Those ideas are not contradictory. In fact, that is what mature public-health communication looks like. The broader concern here may not even be Ebola itself. It may be what this debate reveals about the state of America’s public-health infrastructure and confidence in it.

Over the last few years, the U.S. has seen repeated restructuring, funding battles, staffing shortages, and political attacks involving agencies like the CDC, NIH, USAID, and international public-health partnerships, so when Americans hear that their government may prefer offshore quarantine arrangements instead of domestic treatment, some will inevitably ask:

• Does the government still trust its own system?

• And if it doesn’t, should the public?

These are difficult questions, but they are worth discussing honestly instead of reducing everything to partisan slogans or viral panic. Because public health is not only about controlling disease. It is also about what obligations societies owe to one another when fear enters the room.

Share

While not required, any support is greatly appreciated, including purchasing a copy of my new book.

Yesterday, the CDC held a detailed media briefing regarding the ongoing Andes hantavirus response connected to the cruise ship outbreak that has now led to exposed Americans being monitored in the United States.

The call itself lasted about 20 minutes and the transcript can be found here.

But beneath the surface, it revealed something much larger:
a public health system attempting to navigate the post-COVID world, where every word is scrutinized, every uncertainty becomes a conspiracy theory online within minutes, and every reassurance is immediately compared to February 2020.

What struck me most was not fear.

It was caution.

Not just caution about the virus itself, but caution in communication.

Because the CDC appears to understand that this situation is no longer only about virology or epidemiology. It’s also about credibility, trust, and how institutions communicate uncertainty in an era where social media rewards the most alarming interpretation possible.

First: What Is Actually Happening?

The outbreak in question involves Andes virus, a hantavirus strain primarily found in South America that is unusual because it has demonstrated limited human-to-human transmission in prior outbreaks.

That point matters because most hantaviruses, including the strains more familiar in the United States, such as Sin Nombre virus, are generally associated with rodent exposure and are not known for sustained person-to-person spread.

The outbreak became internationally significant after reports emerged involving passengers aboard a cruise ship, followed by monitoring and repatriation efforts involving American citizens.

According to the CDC briefing:

• CDC activated its emergency response immediately

• More than 100 CDC staff are currently involved

• Teams were deployed to the Canary Islands

• CDC personnel accompanied passengers back to the United States

• Additional teams are now conducting assessments and monitoring in Nebraska

That operational response is substantial.

And yet, throughout the briefing, officials repeatedly emphasized:

“The risk to the general public remains low.”

That sentence alone is enough to trigger flashbacks for many Americans.

The reporters on the call clearly understood that too.

The “Mildly Positive” PCR Result Became the Center of the Briefing

The most important scientific clarification today involved the now widely discussed “mildly positive” American passenger.

Over the past couple of days, headlines and social media posts began circulating suggesting:

• asymptomatic spread

• silent infections

• hidden transmission

• possible community spread

However, during the briefing, CDC officials significantly reframed the situation.

When directly questioned by Reuters about the reported positive passenger, officials clarified that the overseas test was actually considered inconclusive because:

“there was a positive and a negative.”

They stated repeat testing is currently underway in the United States.

That distinction is extremely important scientifically.

A PCR assay amplifies genetic material repeatedly until a signal crosses a threshold. In some cases:

• the signal is extremely weak

• one target amplifies while another does not

• replicate tests disagree

• contamination is possible

• results sit near the assay’s limit of detection

In those situations, laboratories often use terms like:

• equivocal

• indeterminate

• borderline

• inconclusive

Importantly:
A low-level or inconclusive PCR result does not automatically prove:

• active infection

• contagiousness

• asymptomatic transmission

• meaningful viral replication

This is why more testing is needed in this situation.

CDC Is Clearly Trying to Avoid Overstating Risk

One thing I found notable throughout the briefing was what CDC officials didn’t say.

They did not claim:

• casual airborne spread

• sustained community transmission

• grocery-store-level risk

• widespread asymptomatic infection

In fact, officials repeatedly continued framing risk around exposure assessments and monitoring rather than confirmed transmission chains. Even when discussing airline passengers and secondary contacts, the CDC carefully described these as:

• precautionary monitoring efforts

• exposure-based follow-up

• conservative containment strategies

That distinction matters because the online conversation has rapidly escalated into worst-case-scenario territory.

At this point, social media contains claims ranging from:

• “this is airborne Ebola”
  to

• “CDC is hiding asymptomatic spread”
  to

• “this will become another lockdown situation”

Nothing presented during today’s briefing supported those conclusions. That doesn’t mean the outbreak is irrelevant. It means there is currently a large gap between:

“public health officials are taking this seriously”

and

“evidence shows widespread uncontrolled spread.”

Those are not the same statement.

Why the 42-Day Monitoring Window Sounds So Scary

Another major point of public anxiety is the 42-day monitoring period. Forty-two days sounds dramatic.

But incubation periods are not the same thing as contagiousness.

Long monitoring windows often reflect:

• rare-event caution

• incomplete understanding of exact exposure timing

• desire to capture delayed symptom onset

• conservative public health strategy

CDC also clarified something else important:
they are currently recommending testing mainly for symptomatic individuals rather than universal asymptomatic screening.

Again, that matters.

If officials believed efficient silent transmission was occurring, you would expect:

• mandatory quarantine orders

• aggressive serial PCR testing

• broad asymptomatic screening

• far more restrictive movement limitations

Instead, CDC repeatedly described current monitoring efforts as cooperative and largely voluntary.

The Entire Briefing Was Really About Trust

Honestly, the virology almost felt secondary at times.

This briefing was fundamentally about trust.

You could hear it in the wording:

• “transparent communication”

• “daily coordination”

• “working closely with states”

• “keeping communities safe”

• “sharing real-time information”

The CDC seems acutely aware that every infectious disease event is now interpreted through the emotional memory of COVID.

That creates a nearly impossible communication challenge.

If officials reassure people too strongly: they’re accused of hiding information.

If officials speak too aggressively: panic spreads faster than the pathogen itself, and social media algorithms reward the most emotionally extreme interpretation every single time.

What We Actually Know Right Now

Based on today’s briefing, here is the clearest evidence-based summary possible:

• Andes virus can rarely spread person-to-person

• CDC is taking the outbreak seriously

• Exposed Americans are currently under monitoring

• One reported American PCR result has now been described as inconclusive

• No evidence presented today demonstrated widespread casual community spread

• The current risk to the general public remains low based on available evidence

And perhaps most importantly:

There is a profound difference between:

“We are monitoring carefully because uncertainty exists”

and

“This is definitely the next pandemic.”

Right now, much of the public conversation keeps collapsing those two ideas together. That may ultimately become the most important lesson from this entire situation.

Share

Although not required, any support is greatly appreciated, including supporting my recently published book.

Over the last several days, social media has turned Andes virus (a type of hantavirus) into the latest “this could be the next COVID” panic cycle. Screenshots, speculation, and half-true statements are spreading faster than the facts themselves.

Now, we finally have something more concrete: interim CDC guidance related to the ongoing Andes virus investigation connected to passengers aboard the M/V Hondius cruise ship.

After reading the entire document, here’s the key takeaway: This is a serious public health investigation, but it is not evidence of an impending global pandemic. What the CDC released is essentially a detailed containment and monitoring playbook for a rare virus with limited but documented person-to-person transmission.

That nuance matters.

First: What Is Andes Virus?

Andes virus is a type of hantavirus found primarily in South America. Unlike the hantaviruses more commonly seen in the United States, Andes virus is notable because it can spread person-to-person under certain circumstances.

That’s why public health authorities are taking this outbreak seriously.

However, “can spread person-to-person” does NOT automatically mean “spreads easily.”

Those are very different concepts.

The CDC guidance repeatedly frames transmission around:

• prolonged close contact,

• shared living spaces,

• bodily fluids,

• caregiving exposure,

• and extended indoor interactions.

This is not behaving like SARS-CoV-2, measles, or influenza. If Andes virus was, then I would be much more concerned.

Why the Cruise Ship Situation Triggered Alarm

The guidance focuses heavily on passengers aboard the M/V Hondius because cruise ships create an environment where:

• people share enclosed spaces,

• exposures are difficult to reconstruct,

• and prolonged interactions are common.

The CDC therefore classified anyone aboard during a specific exposure window as “high-risk contacts.” That classification sounds dramatic online, but from a public health standpoint, it’s actually fairly logical. When authorities don’t yet know exactly who had close exposure, they cast a wider net early. That’s precautionary, not proof the virus is spreading uncontrollably.

The Internet Is Misreading the “42-Day Monitoring” Window

One thing fueling fear online is the CDC’s recommendation for 42 days of monitoring after exposure.

People see “42 days” and assume:

“This must be incredibly contagious or catastrophic.”

Not necessarily. The CDC lists the incubation period as ranging from 4 to 42 days, with a median of 18 days. Public health agencies generally monitor for the outer bounds of incubation periods when they want to avoid missing cases.

That’s not unusual.

For comparison:

• rabies monitoring can extend for months,

• tuberculosis investigations can span weeks to months,

• and Ebola monitoring historically lasted 21 days.

Long monitoring periods are often about caution and surveillance, not transmissibility.

The Exposure List Tells Us Something Important

One of the most revealing parts of the guidance is the actual exposure questionnaire.

The CDC asks about:

• kissing or hugging,

• sharing a bed,

• sexual contact,

• sharing utensils,

• sharing drinks,

• exposure to saliva or respiratory secretions,

• caring for sick individuals,

• and spending prolonged time within 6 feet in enclosed spaces.

That list matters because it gives us clues about the kinds of interactions considered most concerning.

This is not:

“Someone walked past me in a grocery store.”

This is much closer to:

“Close, prolonged, intimate, or caregiving exposure.”

Again, important distinction.

Why the CDC Is Recommending Masks and Travel Restrictions

The guidance advises high-risk contacts to:

• avoid commercial air travel,

• minimize activities outside the home,

• avoid crowded events,

• wear masks indoors around others,

• and avoid sharing personal items.

Some people online are interpreting this as proof authorities believe widespread airborne transmission is occurring. However, infection control guidance is often intentionally conservative early in an investigation, especially when dealing with a rare pathogen where data is still evolving.

Public health agencies would rather temporarily overestimate risk than underestimate it.

That’s especially true when:

• the disease can be severe,

• transmission dynamics are incompletely understood,

• and the number of total known cases remains small.

The Most Important Thing Missing From the Panic Narratives

What’s not in the CDC document may actually be more important than what is.

There is:

• no evidence of sustained community transmission,

• no evidence of easy casual spread,

• no indication of explosive exponential growth,

• and no indication this virus suddenly mutated into something fundamentally different.

The guidance is structured around containment and monitoring, not mass mitigation measures for the general public. That distinction is critical. If this were behaving like an easily transmissible respiratory virus, the recommendations and tone would look very different.

Public Health Is Trying to Avoid Two Mistakes at Once

Right now, public health officials are balancing two competing risks:

Risk #1:

Underreacting to a potentially dangerous outbreak.

Risk #2:

Triggering unnecessary panic through overinterpretation.

Unfortunately, social media tends to amplify only the most emotionally charged interpretation possible.

That’s why you’re seeing:

• “They’re hiding the truth!”

• “This is airborne Ebola!”

• “This is the next COVID!”

• “Governments are preparing for lockdown!”

None of those claims are supported by the actual CDC guidance document.

What About the “Weakly Positive” PCR Case?

The Department of Health and Human Services recently announced that one of the American passengers going to Nebraska has a “weakly positive” PCR test for Andes virus.

PCR tests detect viral genetic material. A “weakly positive” result generally means a low amount of detectable viral RNA was found, but that does not mean the result is automatically meaningless or “fake.”

A low-level PCR positivity can happen for several reasons, including:

• someone may be very early in infection,

• someone may be later in infection,

• the sample quality may vary,

• or the viral burden may simply be low at that moment.

Importantly, public health officials are clearly treating this as a real positive requiring monitoring, not as a laboratory error.

According to reporting from Nebraska Medicine and multiple news outlets, the PCR-positive passenger is currently reported to be asymptomatic. Another passenger is reported to have mild symptoms but has not necessarily tested positive at this time.

That distinction matters.

A positive PCR does NOT automatically mean:

• severe disease,

• imminent deterioration,

• or high contagiousness.

In fact, finding a case before severe illness develops is exactly what active monitoring systems are designed to do.

Why Some People Are Going to Nebraska While Others May Quarantine at Home

The CDC specifically states that high-risk contacts may choose:

• home-based monitoring with modified activities,
  or

• facility-based management at the National Quarantine Unit in Nebraska.

That’s an important detail because it tells us officials are not treating this like a virus that spreads easily through casual public contact. If they believed casual exposure in everyday settings posed major transmission risk, home isolation would likely not even be an option.

Instead, health departments are instructed to evaluate:

• whether someone can realistically follow isolation guidance,

• whether they have an appropriate home setup,

• and whether they can safely separate from others if symptoms develop.

The CDC isn’t relying on blind trust alone. There are monitoring systems, daily check-ins, travel restrictions, and risk assessments, and the transmission patterns we know about still point toward close, prolonged exposure, not casual spread in the grocery store.

The Nebraska unit exists partly because some individuals:

• may not have an ideal home environment,

• may prefer closer medical supervision,

• or may want rapid access to specialized care if symptoms develop.

That’s very different from evidence of uncontrolled community spread. In many ways, this is exactly what a cautious but proportionate public health response looks like:
identify high-risk exposures, monitor carefully, provide layered containment options, and escalate care only when needed.

What People Should Actually Do

For the overwhelming majority of people reading this:

• your personal risk remains very low

• there is no recommendation for widespread behavior changes

• and there is no evidence supporting panic buying, avoiding travel broadly, or assuming a pandemic is imminent.

But there is value in:

• following updates from credible public health sources

• understanding how transmission actually occurs

• and resisting the urge to treat every emerging infection as an apocalyptic event.

Because fear spreads faster than viruses ever could, and in 2026, that may be the most contagious thing of all.

Share

Although not required, any support is greatly appreciated, including supporting my new book.

The headlines are almost engineered to trigger déjà vu or read like a movie script.

A cruise ship.
A deadly virus.
Passengers being tracked across countries.
A rare strain capable of human-to-human transmission.

And suddenly social media is asking the same question again:

“Is this the next COVID-19?”

“Is this 2020 all over again?!”

The short answer is no.

That doesn’t mean the situation should be ignored. It means it should be understood correctly.

Right now, health officials are monitoring passengers linked to an outbreak of the Andes strain of hantavirus aboard the cruise ship MV Hondius. Several deaths have been reported, and international contact tracing is underway.

That sounds alarming because it is serious for the people directly affected.

However, “serious” and “likely to become a global pandemic” are not the same thing.

People struggle with nuance during outbreaks. Public health communication works best somewhere in the middle.

First: What Is Hantavirus?

Hantaviruses are a family of viruses primarily carried by rodents.

Humans usually become infected through exposure to aerosolized rodent urine, droppings, or saliva, often in enclosed spaces like cabins, sheds, barns, crawlspaces, or poorly ventilated areas.

In the Americas, hantavirus can cause a severe illness called Hantavirus Pulmonary Syndrome (HPS), which affects the lungs and cardiovascular system.

The strain currently making headlines is the Andes virus, found primarily in parts of Argentina and Chile. This is the key detail driving panic:

The Andes strain is the only known hantavirus that has demonstrated documented human-to-human transmission, but this needs context because many people are hearing:

“Human-to-human transmission exists.”

…and interpreting that as:

“This spreads like COVID and is airborne.”

Those are very different things.

Why This Is Not the Next COVID-19

COVID-19 succeeded as a pandemic virus because it had several traits working in its favor:

• efficient respiratory spread

• spread from mildly symptomatic or asymptomatic people

• rapid international transmission

• short serial intervals

• widespread susceptibility

• extremely high transmissibility in indoor air

• high rate of mutations

SARS-CoV-2 spread extraordinarily well.

Hantavirus does not.

Even the Andes strain, the one capable of person-to-person spread, has historically required prolonged close contact, often involving household members, intimate partners, or caregiving situations.

That is fundamentally different from:

• walking through a grocery store

• sharing an elevator

• passing someone in public

The current outbreak appears linked to a very unusual circumstance:

• a confined cruise environment

• potential shared exposure before boarding

• close quarters over prolonged periods

• international travel complicating tracing efforts

Even the World Health Organization has emphasized that the broader public health risk remains low.

That matters.

The “40% Mortality Rate” Statistic Needs Context Too

One reason these headlines feel terrifying is the repeated mention of a roughly 40% fatality rate for Andes hantavirus. It is true that hantavirus can absolutely be devastating, but mortality rate alone does not determine pandemic potential.

Ebola kills far more people proportionally than COVID-19 did. Yet Ebola has never become a global airborne pandemic because it spreads inefficiently and requires close-contact exposure.

A virus that is highly lethal often spreads less effectively because severely ill people tend to become isolated quickly. COVID-19’s danger came partly from the opposite dynamic: people could spread it before realizing they were sick.

That distinction matters enormously in epidemiology.

So Why Are Authorities Taking This So Seriously?

Because good public health responds aggressively before certainty exists Contact tracing and monitoring are appropriate. Investigating clusters is appropriate. Watching for additional transmission chains is appropriate.

This is exactly what health agencies are supposed to do when a rare pathogen with known severe disease appears in an unusual setting.

The fact that officials are monitoring passengers in multiple countries does not automatically mean catastrophe is imminent. It means surveillance systems are functioning.

What People Are Getting Wrong Online

1. “This spreads through the air like COVID-19.”

There is currently no evidence suggesting widespread casual airborne transmission similar to SARS-CoV-2. Historical Andes virus transmission has generally required close, prolonged contact.

2. “Cruise ships are causing the outbreak.”

The ship is likely the amplification setting, not necessarily the original source. Investigators believe some passengers may have been exposed during travel in Argentina or Chile before boarding.

3. “Health agencies are hiding how bad this is.”

Actually, the opposite is happening. Agencies are publicly reporting monitoring efforts, tracing contacts, and openly discussing uncertainty in real time.

4. “This means another lockdown is coming.”

There is no evidence supporting that scenario. None.

A Better Way to Think About Risk

Medicine works best through a balanced approach by asking questions such as:

• How severe is the disease?

• How efficiently does it spread?

• Under what conditions does it spread?

• Is transmission sustained in the community?

• Are cases traceable?

• Are infections occurring through casual contact?

Right now:

• the disease itself is serious

• the outbreak is important

• the public health response is ongoing

• but the evidence does not support comparisons to early COVID-19 dynamics

Those distinctions matter.

What Should Regular People Actually Do?

For most people, the answer is not panic.

It’s awareness.

If you’re traveling in areas where hantavirus is endemic:

• avoid exposure to rodents and rodent droppings

• don’t sweep enclosed contaminated spaces dry

• ventilate cabins or sheds before cleaning

• use wet-cleaning/disinfectant methods instead of aerosolizing debris

If you recently traveled in affected regions and develop fever, severe muscle aches, or breathing symptoms, seek medical care and mention the exposure history.

That’s rational preparedness, not doomscrolling.

The Bigger Problem: Trauma From the Last Pandemic

Part of what’s happening right now isn’t really about hantavirus.

It’s about unresolved societal trauma from COVID-19.

People remember:

• confusing messaging

• uncertainty

• rapidly changing guidance

• early underestimation

• overwhelmed hospitals

• fear of the unknown

So now every outbreak headline gets filtered through that memory, but good risk assessment requires resisting the urge to replay 2020 every time a new pathogen appears.

Sometimes, an outbreak stays contained.

Sometimes, a scary disease is still a low population-level risk. For now, that still appears to be the case.

Share

Although not required, any support is greatly appreciated.

NIH Director and former acting CDC Director Jay Bhattacharya’s Washington Post op-ed title is built around a sentence that sounds reassuring: the CDC, under my leadership, will “follow the evidence.” The problem is not the slogan. The problem is what is really happening.

The controversy is simple: CDC scientists reportedly prepared a Morbidity and Mortality Weekly Report showing that COVID vaccination reduced emergency visits and hospitalizations among healthy adults by about half this past winter. The report was not published. The Department of Health and Human Services (HHS) said the issue was methodology. Bhattacharya now says this was scientific rigor, not interference.

However, here is the core problem: scientific rigor does not require burying inconvenient data.

Bhattacharya focuses his critique on the “test-negative design,” a common real-world method used to estimate vaccine effectiveness. Is it perfect? No. No observational design is, but imperfect is not the same as invalid. The World Health Organization has described test-negative design as an efficient and feasible method for assessing COVID vaccine effectiveness, while acknowledging potential biases. KFF notes it has become a prevalent approach for monitoring influenza and COVID vaccine effectiveness in real-world settings.

That matters because Bhattacharya’s argument depends on making this method sound uniquely suspect. It is not. It is standard. It has limitations, but those limitations are usually handled by explaining them, sensitivity analyses, comparison with other studies, and transparent discussion. Not by preventing the public from seeing the results.

That is the real tell.

If the concern was truly methodological, the CDC could have published the findings with caveats. It could have included an editor’s note. It could have requested revision. It could have released the data and explained the uncertainty. Instead, the public got nothing.

That is not “following the evidence wherever it leads.”
That is deciding the evidence cannot be trusted unless leadership likes where it leads.

Bhattacharya also argues that MMWR is not formally externally peer reviewed, which is true. However, MMWR has long been CDC’s main vehicle for timely public-health findings, and CDC itself describes it as the agency’s primary source for “timely, reliable, authoritative, accurate, objective, and useful” public-health information. CDC also states that MMWR articles undergo rigorous multilevel clearance, including scientific and editorial review.

So the rhetorical move here is clever but misleading: downgrade MMWR when it publishes something inconvenient, then invoke the CDC director’s authority as the final gatekeeper.

That is not transparency. That is centralization.

The op-ed also says media reports were misleading because the CDC director had not cleared the report. However, that misses the public concern. The concern is not whether the acting director technically has sign-off power. The concern is whether that power is being used to raise legitimate scientific questions or to suppress vaccine-benefit data during a politically charged fight over vaccine policy.

The context matters. Bhattacharya is not a neutral bystander suddenly discovering methodological caution. He is a longtime critic of the CDC’s pandemic response and coauthor of the Great Barrington Declaration. The Washington Post reported that he was installed as acting CDC head while continuing as NIH director, in a broader HHS shake-up led by Robert F. Kennedy Jr.

That does not automatically make every decision political, but it makes transparency more important, not less.

The honest version of this op-ed would have said:

We disagreed with the methodology. Here are the reviewer comments. Here is the manuscript. Here are the data limitations. Here is why we treated this COVID vaccine-effectiveness study differently from other studies using similar methods.

Instead, we got a trust-me bro essay about trust.

That is the deeper problem. Public trust is not restored by saying “rigor,” “radical transparency” and “gold standard science” over and over. Public trust is restored when agencies show their work, publish uncomfortable findings, and let the scientific community evaluate the evidence.

If CDC leadership believes a study is flawed, the answer is more transparency.

Not less. Because the public-health standard cannot become when:
Evidence counts only after political leadership clears it.

Share

There’s a moment making the rounds where Joe Rogan says he texted Donald Trump about ibogaine and got back something to the effect of: “Sounds great…do you want FDA approval? Let’s do it.”

Even if you’re enthusiastic about new treatments (and we should be) this should make you uncomfortable.

Not because of who sent the text, but because of what the text implies about how drugs should (and should not) get approved.

The FDA Is Supposed to Be Boring

Drug approval is intentionally slow, methodical, and, boring.

• Phase 1: Is it safe in humans?

• Phase 2: Does it show a signal of benefit?

• Phase 3: Does it actually work, at scale, compared to existing treatments?

Then comes manufacturing standards, dosing consistency, labeling, and post-marketing surveillance. This is the unglamorous work that helps prevent people from getting hurt.

There are ways to accelerate this process such as Breakthrough Therapy designation, Fast Track, Accelerated Approval, but even those still require data. Not enthusiasm, not anecdotes, and not a compelling podcast segment.

So when approval is framed like something that can be greenlit after a persuasive conversation, it doesn’t just sound off; it undercuts the entire premise of evidence-based medicine.

What’s Actually Known About Ibogaine

Ibogaine is interesting. It may end up being important and it absolutely deserves study.

However, here’s where we are right now:

• The human data are small, mostly observational, often without control groups.

• Many reports focus on short-term withdrawal relief and reduced cravings; not durable remission.

• Long-term outcomes are inconsistent and nowhere near the “80–90% cure” being touted by Joe Rogan and President Trump.

• There are real safety signals, including ataxia, dangerous heart rhythm disturbances (QT prolongation), arrhythmias, and reported deaths.

In other words: promising, but early and not risk-free.

That’s exactly the kind of profile that calls for careful trials, not shortcuts.

The False Choice We Keep Making

A common rebuttal is: “How can ibogaine be worse than fentanyl addiction?”

It’s a powerful question, and a misleading one.

We’re not choosing between “ibogaine” and “fentanyl on the street.”
We already have evidence-based treatments that reduce overdose risk and save lives:

• Buprenorphine

• Methadone

• Naltrexone

The real question is whether ibogaine can prove that it’s safe and effective compared to or alongside what already works.

That requires trials. Careful dosing, cardiac monitoring protocols, and long-term follow-up.

It does not require a shortcut.

Why the Optics Matter (Because They Become Reality)

You might argue: “It’s just a text. No one is actually approving a drug over SMS.”

Fair, but messaging shapes behavior.

When high-profile figures present early data like a near-miracle and pair that with the suggestion that approval is just a decision away, it creates a cascade:

• Patients hear “cure” and look for access anywhere they can find it

• Clinics spring up in loosely regulated settings

• Safety standards vary widely

• Adverse events become more likely

• Trust erodes when outcomes don’t match the hype

We’ve seen this movie before, and it always ends the same way: people get hurt first, and the science catches up later.

Influence vs. Evidence

Here’s the core issue: Influence is not a substitute for evidence.

It doesn’t matter if the influencer is a podcaster, a billionaire, or a president. The standard should be the same:

• What does the data actually show?

• How strong is that evidence?

• What are the risks?

• Who has validated it independently?

When those questions get replaced with “this sounds promising,” the system stops being scientific and starts being susceptible to whoever has the loudest voice or the closest access to power.

That’s not innovation, it’s vulnerability.

Yes, Fund the Research But Don’t Skip the Work

If the goal is to fund rigorous ibogaine research, then let’s do that.

Design well-controlled trials. Standardize dosing. Screen for cardiac risk. Track long-term outcomes. Publish the results whether they are good or bad.

That’s how you turn a promising idea into a safe, usable therapy.

However, pairing that effort with inflated claims and the suggestion of rapid approval undermines the very process that would make the drug credible in the first place.

The Bottom Line

We should be aggressive about solving the opioid crisis and other issues such as PTSD. Lives depend on it, but urgency doesn’t justify abandoning standards. It demands that we get the science right.

Because the FDA isn’t a barrier to breakthroughs.
It’s what separates breakthroughs from well-packaged mistakes.

If a treatment truly works, it doesn’t need a text message to get approved.

It needs evidence, and if access to power starts to matter more than quality of data, then that’s not speeding up science. That’s how you break it.

Share

If it feels like everyone has allergies now…you’re not imagining it.

More kids are carrying epinephrine auto-injectors. More adults are developing seasonal allergies later in life. Asthma rates have climbed. Food allergies are more common than they were a generation ago, and every spring, it feels like pollen is trying to personally ruin your life.

So what’s going on?

This question—why allergies are increasing—is one of the central threads I explore in my book, All About Allergies. Because once you understand the “why,” everything else, including symptoms, treatments, and even misinformation starts to make a lot more sense.

Let’s break it down.

The Immune System: A System That Learns

Your immune system isn’t just a shield; it’s a learning system.

From birth, it’s constantly making decisions:

• What is dangerous?

• What is harmless?

• What should I ignore?

In a well-calibrated system, pollen is ignored. Peanuts are tolerated. Dust mites are background noise.

However, in allergic individuals, the immune system makes a mistake. It flags something harmless as dangerous and then doubles down on that decision.

That’s allergy, and one of the big ideas in All About Allergies is this:

Allergic disease isn’t random. It’s a pattern of mislearning.

So the real question becomes: Why is the immune system making more mistakes now than it used to?

1. The Hygiene Hypothesis (and Its Modern Upgrade)

One of the most important clues comes from what’s called the hygiene hypothesis, though I explain in the book why that name doesn’t quite capture the full picture.

It’s not that cleanliness is bad.

It’s that our immune systems evolved expecting exposure to a wide range of microbes early in life, and now they’re getting less of that input.

Historically, kids grew up:

• Around animals

• In dirt

• In larger households

• With more microbial exposure

Today, many children grow up:

• In cleaner, more controlled environments

• With less microbial diversity

• Spending more time indoors

That early exposure helps “train” the immune system. Without it, the system can become overly reactive. Instead of saying “this is harmless,” it says:
“This is a threat. Respond aggressively.”

That’s how you get allergies.

2. The Microbiome Shift

In All About Allergies, I spend a lot of time on something most people don’t think about: the microbiome.

The trillions of bacteria living in and on your body aren’t just along for the ride, they actively help regulate your immune system, and over the past few decades, we’ve changed them dramatically.

Key factors include:

• Antibiotic use (especially early in life)

• Diets low in fiber, high in processed foods

• Increased C-section rates

• Changes in breastfeeding patterns

• Urban living

A less diverse microbiome means less immune regulation, and when regulation drops, allergic responses become more likely.

3. Why Spring Feels Like It’s Getting Worse Every Year

Let’s talk about what you’re actually experiencing.

Pollen seasons are getting:

• Longer

• More intense

• More unpredictable

Climate change is a major driver here.

Higher temperatures and increased carbon dioxide levels allow plants to:

• Produce more pollen

• Start earlier

• Last longer

So even if your immune system stayed exactly the same, You’re being exposed to more allergens, for longer periods of time.

That’s not subtle. Your body feels that.

4. Pollution: The Multiplier Effect

Pollution doesn’t just irritate your airways; it changes how your immune system reacts.

It can:

• Damage the lining of your respiratory tract

• Make allergens more potent

• Increase inflammation

So, when you combine pollen and pollution…

You don’t just get symptoms. You get amplified symptoms.

5. The Allergic March

Another concept I walk through in the book is something called the allergic march:

Eczema in infancy often leads to higher risk of developing food allergies, seasonal allergies and asthma. These aren’t separate problems. They’re connected expressions of the same underlying immune pattern. Which is why it can feel like allergies are “everywhere” because they often travel together.

6. It’s Not Just Awareness—It’s Real

Yes, we’re better at diagnosing allergies now.

Yes, people talk about them more.

However, even after accounting for that, Rates are still rising.

This is a real shift, not just a perception problem.

The Bigger Picture

When you zoom out, the pattern becomes clear:

• The immune system depends on early-life training

• Our environments have changed rapidly

• Our microbiomes have shifted

• Allergen exposure has increased

• Pollution amplifies the response

Put that together, and you get:

More people developing allergies, and more severe symptoms when they do.

So What Actually Helps?

This is where people usually want a quick fix.

But as I emphasize throughout All About Allergies:

When the problem is complex, the solution is rarely simple.

Still, there are evidence-based strategies that make a real difference:

• Early introduction of allergenic foods (for infants)

• Reducing unnecessary allergen avoidance

• Using medications correctly (not randomly)

• Considering immunotherapy when appropriate

• Improving environmental control

Also, this is just as important:

Learning how to filter good information from bad. Because allergy misinformation everywhere and often sounds convincing.

Why I Wrote All About Allergies

I didn’t write this book just to explain what allergies are.

I wrote it because I kept seeing the same pattern in clinic and online:

People weren’t just confused, they were overwhelmed by symptoms, conflicting advice, and by viral claims that sounded scientific but weren’t.

I built the book to do something different:

• Break down complex immunology into clear, intuitive ideas

• Walk through real conditions (asthma, food allergy, hay fever)

• Explain what actually works and what doesn’t

• Give you a framework to think like a doctor when it comes to your health

Because once you understand why your body is reacting the way it is, you stop chasing random fixes and start making informed decisions.

The Takeaway

Allergies aren’t increasing because people are “weaker.” They’re increasing because we’ve changed the environment faster than our immune systems can adapt.

When a learning system loses the signals it depends on, it starts making mistakes.

Sometimes, those mistakes look like a runny nose.

Sometimes, they look like anaphylaxis.

However, at their core, they’re the same thing:

An immune system trying to protect you; just aiming at the wrong target.

Order All About Allergies Here!

Share

Every spring, my clinic fills up with the same question:

“Why are my allergies so bad this year and what actually works?”

Tree pollen is everywhere right now. Cars are becoming coated in yellow dust. Patients are miserable, and unfortunately, there’s also a lot of misinformation floating around online.

So let’s simplify this.

Here are the 10 most effective, evidence-based ways to control spring allergies (in no particular order).

Keep in mind that this is for educational purposes only and any concerns should be discussed with your personal physician.

1. Start Your Medications Before Symptoms Explode

This is the biggest mistake I see.

Allergy medications work best preventively, not reactively.

If you wait until you’re already congested, itchy, and exhausted, you’re playing catch-up because the inflammation has already started and it’s more difficult to stop.

👉 Start 1–2 weeks before peak pollen season (or as soon as symptoms begin if you’re late).

2. Use a Daily Intranasal Steroid (The MVP)

If I could only recommend one medication, this would be it.

Examples include:

• Fluticasone (Flonase)

• Triamcinolone (Nasacort)

These reduce inflammation at the source.

Key tip:
Most people use them incorrectly. Aim slightly outward (toward the ear), not straight up the nose. Do not snort the medication. As I like to say, “If you taste it, you waste it!”

3. Add a Non-Drowsy Antihistamine

These help with itching, sneezing, and runny nose.

Options:

• Cetirizine (Zyrtec)

• Fexofenadine (Allegra)

• Loratadine (Claritin)

• Levocetirizine (Xyzal)

They’re not as strong as nasal steroids but they’re a great add-on.

4. Consider Allergy Eye Drops

If your eyes are the main problem, don’t rely on oral meds alone.

Look for:

• Olopatadine (Pataday)

• Ketotifen (Zaditor)

These work fast and target the problem directly. Unfortunately, they can burn

5. Rinse Your Nose (Yes, Really)

Saline irrigation (Neti pot or squeeze bottle) helps physically remove pollen.

Think of it as:
“Showering your sinuses.”

It’s simple, cheap, and surprisingly effective. ALWAYS USE DISTILLED WATER! Never tap water unless previously boiled. Always follow the instructions with the device.

6. Shower After Being Outdoors

Pollen sticks to:

• Hair

• Skin

• Clothing

If you don’t rinse it off, you bring it straight into your bed.

This is especially important before sleep.

7. Keep Windows Closed (Even If It’s Nice Out)

I know. This one hurts.

But open windows means pollen flooding your home.

Use:

• Air conditioning

• HEPA filtration if possible

8. Change Clothes When You Get Home

Your outfit is basically a pollen delivery system.

Quick change means less exposure inside your house.

Keep your shoes in one place in your home and wipe down pets’ paws when they come home.

9. Track Pollen Counts (Strategically)

Not all days are equal.

High pollen days:

• Dry

• Windy

• Warm

Lower pollen days:

• After rain

Use this to plan:

• Outdoor exercise

• Yard work

• Kids’ activities

Wearing a mask (surgical, KN95, N95) and eye protection while doing chores can be surprisingly effective.

10. Know When to See an Allergist

If you’re still struggling despite all of this:

• You may need combination therapy

• You may be a candidate for allergy shots (immunotherapy)

• You may not even have allergies (yes, that happens it’s called non-allergic rhinitis)

The Bigger Picture

Here’s the part most people miss:

Allergy treatment isn’t about one magic fix.
It’s about layering strategies.

Medication + environment + habits = control.

When you get that balance right, allergy season becomes manageable.

Want to Understand Why This Works?

I wrote All About Allergies to go deeper than quick tips like this.

Not just:
👉 what to do

But:
👉 why your immune system behaves this way in the first place
👉 how treatments actually work
👉 how to separate real science from internet myths

If you’ve ever felt overwhelmed by conflicting advice, this book is for you.

📘 All About Allergies is available now wherever books are sold.

Final Thought

Every year people tell me:

“I thought I just had to suffer through spring.”

You don’t.

You just need the right tools, and a plan.

Share

Over the past 24 hours, I’ve watched a familiar pattern unfold. A federal court issues a technical ruling about administrative law, and suddenly social media is flooded with claims that:

• A judge has “defied the Supreme Court”

• Unelected “experts” now control vaccine policy

• ACIP has more power than the CDC

• The ruling proves the “administrative state” has taken over

Let’s be clear:

None of that is what the ruling says.

If you’re a physician, scientist, or just someone trying to understand what actually happened—these issues matter.

What the Court Actually Did

The case (brought by groups like the American Academy of Pediatrics and other medical organizations) challenged how recent vaccine policy changes were made.

The judge issued a preliminary injunction—not a final ruling—temporarily pausing:

• Changes to the childhood vaccine schedule

• Newly appointed ACIP members

• Votes taken by that reconstituted committee

This wasn’t about whether vaccines are good or bad. It was about process.

Specifically:

Did the government follow the law when it changed vaccine policy?

The court’s answer (for now): Probably not.

Claim 1: “The judge is defying the Supreme Court”

This is one of the most viral and most misleading claims.

There is no Supreme Court ruling that broadly bans nationwide injunctions.

In fact:

• Federal courts regularly issue nationwide relief in administrative law cases

• The Supreme Court has debated the scope, but has not eliminated the power

So when you see:

“This judge has been rebuked by the Supreme Court”

That’s not a legal argument. That’s rhetoric.

Claim 2: “ACIP is just advisory and this gives them too much power”

This sounds intuitive. It’s also incomplete.

Yes, the Advisory Committee on Immunization Practices is technically advisory. However, here’s what’s missing:

Congress has written multiple laws that explicitly depend on ACIP recommendations, including:

• Insurance coverage under the ACA

• Medicaid vaccine coverage

• Vaccines for Children (VFC) program

• Liability protections under federal law

That means ACIP recommendations are not “just advice.”

They are legally embedded triggers, so the court didn’t “empower ACIP.”

It recognized a reality that already exists: Congress tied vaccine policy to ACIP on purpose.

Claim 3: “This means experts control everything”

This is the classic “administrative state” framing. However, look at the actual structure:

1. Congress writes the laws

2. Expert committees review scientific evidence

3. Agencies implement policy

4. Courts ensure laws are followed

That’s not a power grab, that’s checks and balances. If anything, the ruling reinforces:

The executive branch can’t bypass the system Congress created.

Claim 4: “The President/HHS don’t have authority over agencies”

Another viral oversimplification.

Of course:

• The President oversees the executive branch

• U.S. Department of Health and Human Services oversees agencies like CDC

However, that authority is not unlimited.

Agencies must still follow:

• Statutes passed by Congress

• Administrative law (APA)

• Advisory committee rules (FACA)

This case is about that limitation, not about stripping authority.

Claim 5: “Advisory committees get replaced all the time”

This is partially true and deeply misleading in this context. Yes, administrations can appoint new members, but they must follow the Federal Advisory Committee Act, which requires:

• Fair balance of expertise

• Transparent selection process

• Proper vetting

The court highlighted something important:

The entire ACIP was replaced extremely quickly, which raises legitimate legal questions about whether:

• proper vetting occurred

• balance requirements were met

This isn’t about whether you can appoint new members, it’s about how you do it.

Claim 6: “This makes ACIP more powerful than the CDC Director”

No. The CDC Director still:

• reviews ACIP recommendations

• has authority to accept or reject them

What’s changed here is not power, it’s accountability.

The court is saying:

You can’t bypass the system and still claim the same legal authority.

Claim 7: “This is about vaccines”

This is the biggest misunderstanding of all.

This case is not about:

• vaccine safety

• vaccine efficacy

• or whether schedules should change

It’s about process integrity, and that matters regardless of your views.

Because if process doesn’t matter, then:

• any administration can bypass expertise

• any policy can be rewritten overnight

• scientific review becomes optional

That’s not democracy. That’s instability.

Why This Is Spreading So Fast

Because it taps into three powerful narratives:

1. Distrust of institutions

2. Fear of “unelected experts”

3. Political polarization around vaccines

However, the reality is much less dramatic and much more important:

This is a boring administrative law case that protects how science informs policy.

The Bottom Line

The judge didn’t:

❌ seize power
❌ elevate ACIP above the CDC
❌ defy the Supreme Court

He did one thing:

✅ enforced the process Congress required

Want the full breakdown?

My wife (Melanie Matheu, PhD immunologist) and I went deep on this in our podcast:

🎙️ From Bench to Bedside Podcast

We break down:

• what ACIP actually does

• why this ruling matters

• and what this means for future vaccine policy

It’s exactly the kind of “MD + PhD” conversation we love! We cut through noise and get to the science and the law.

Final Thought

You don’t have to agree with every vaccine policy.

You don’t have to trust every institution.

However, if we abandon process, evidence, and law, we don’t get more freedom. We get chaos, and that helps no one, least of all patients.

If this helped you understand what’s actually going on, consider sharing it.

Because right now, the loudest voices aren’t the most accurate ones.

Share

Dr. Oz recently announced a new federal program on the Centers for Medicare & Medicaid Services (CMS) website.

It’s called MAHA ELEVATE, and it’s about to distribute $100 million in federal funding to organizations promoting lifestyle and “functional medicine” interventions.

At first glance, that may sound reasonable, even appealing. After all, who could be against encouraging exercise, nutrition, sleep, and stress management?

However, as with many things in health policy, the details matter, and once you look closely, some important questions emerge.

What Is the MAHA ELEVATE Program?

The MAHA ELEVATE model is a new pilot program from the CMS Innovation Center, the part of Medicare responsible for testing new healthcare delivery ideas.

The program will:

• Distribute $100 million in grants

• Fund up to 30 organizations

• Run for three years starting in September 2026

• Test programs focused on nutrition, exercise, sleep, stress reduction, and other lifestyle interventions

The stated goal is straightforward:

Test whether “whole-person health” programs can improve outcomes and reduce healthcare spending for Medicare beneficiaries.

In theory, this sounds perfectly aligned with modern medicine. Preventive care and lifestyle changes are essential parts of good health.

However, the program includes something more controversial. It explicitly invites participation from “functional medicine” programs.

The Problem With “Functional Medicine”

The phrase functional medicine sounds scientific, but it is not a recognized medical specialty.

Instead, it’s a loosely defined umbrella term used by a large wellness industry that often includes:

• expensive supplement regimens

• unvalidated laboratory testing

• restrictive elimination diets

• vague “root cause” narratives about chronic disease

Many functional medicine clinics charge patients thousands of dollars out-of-pocket for services that are not supported by high-quality evidence.

To be clear, some ideas promoted under the lifestyle medicine umbrella—nutrition counseling, exercise programs, stress management—are absolutely evidence-based, but functional medicine as a brand has a long history of mixing legitimate health advice with pseudoscience. And that’s where the concern arises.

Medicare Already Covers Lifestyle Medicine

One of the arguments used to promote programs like MAHA ELEVATE is that the healthcare system ignores lifestyle.

That simply isn’t true.

Medicare already funds several major evidence-based lifestyle programs, including:

• The Medicare Diabetes Prevention Program

• Cardiac rehabilitation

• Pulmonary rehabilitation

• Obesity counseling

• Medical nutrition therapy

These programs are not fringe ideas. They are built on decades of clinical research showing that structured lifestyle interventions can improve outcomes.

So the question becomes:

What exactly is MAHA ELEVATE funding that Medicare isn’t already covering?

If the answer is high-quality preventive care, that’s great.

If the answer is unproven wellness programs, that’s another story.

This Is Taxpayer Money

The MAHA ELEVATE model is funded through the CMS Innovation Center, which was created by the Affordable Care Act to test new healthcare payment models.

That means the program is funded by federal taxpayer money.

Pilot programs are important. They allow us to test new ideas before scaling them nationally. However, they also require clear scientific standards and strong oversight.

If the criteria for participation are too vague, we risk funding programs that:

• lack rigorous evidence

• rely on questionable health claims

• prioritize wellness branding over medical outcomes

In other words: We could end up subsidizing the wellness industry with federal healthcare dollars.

The Real Question

None of this means yoga, nutrition, or stress management are bad ideas.

Far from it.

Lifestyle changes are among the most powerful tools we have for preventing chronic disease.

But when the federal government launches a $100 million program tied to concepts like “functional medicine” and “root cause health,” the standards need to be clear.

The real question isn’t whether lifestyle medicine matters.

It’s this:

Will this program produce rigorous evidence that improves patient care, or will it fund loosely defined wellness programs that already thrive outside the medical system?

Taxpayers deserve to know the difference.

Why This Matters

America is facing a massive chronic disease crisis.

Heart disease, diabetes, obesity, and dementia are driving healthcare costs higher every year.

If MAHA ELEVATE successfully tests programs that reduce those costs while improving health, it could be an important step forward.

However, if it becomes a vehicle for unproven wellness interventions, it risks doing the opposite—diverting resources away from evidence-based care.

That’s why this program deserves close scrutiny.

Because when it comes to healthcare policy, good intentions are not enough.

Evidence matters, and when federal dollars are involved, accountability matters even more.

Share

Although not required, any support is greatly appreciated.

Podcasts are powerful. They allow long conversations, nuance, and the ability to explore complicated ideas in ways traditional media often cannot. However, the same format that enables thoughtful discussion can also amplify misinformation, especially when confident claims are presented without scrutiny.

A recent episode of The Joe Rogan Experience featuring attorney Aaron Siri is a case study in how vaccine misinformation spreads in modern media. The conversation moves quickly through a series of familiar talking points: vaccines are treated like a “religion,” pharmaceutical companies supposedly cannot be sued, childhood vaccines allegedly were never tested against placebo, measles was harmless before vaccines, and even that measles infection might somehow be beneficial.

Each claim sounds persuasive when presented confidently in isolation, but once examined carefully, the arguments rely heavily on rhetorical framing, incomplete statistics, and misleading interpretations of history.

Let’s walk through several of the most prominent claims.

Claim #1: “Vaccines Are a Religion”

One of the first rhetorical moves in the conversation is to frame vaccination as a belief system rather than a scientific question. The implication is simple: if vaccines are treated like a religion, then questioning them becomes an act of intellectual courage rather than a disagreement with scientific evidence.

However, the comparison breaks down quickly. Religion is based on faith and doctrine. Scientific medicine operates through evidence and revision. When new data emerges, recommendations change. Treatments are abandoned, updated, or improved In fact, the willingness to change recommendations in response to new evidence is a defining feature of science.

Guidelines for COVID-19 vaccines evolved. Flu vaccine formulations change every year. Screening recommendations shift as new data accumulates. That process can be messy, and sometimes frustrating, but it is the opposite of dogma. Calling science a religion isn’t an argument, it’s a rhetorical strategy designed to sidestep evidence.

Claim #2: “You Can’t Sue Vaccine Companies”

Another common claim in the discussion is that vaccines are unique because manufacturers supposedly have complete legal immunity.

The reality is more complicated.

In the early 1980s, a wave of lawsuits related to the diphtheria-tetanus-pertussis (DTP) vaccine threatened the entire vaccine supply. Manufacturers began leaving the market, and policymakers feared that the country could lose the ability to produce essential vaccines.

In response, Congress passed the National Childhood Vaccine Injury Act of 1986, which created the Vaccine Injury Compensation Program (VICP).

This program established a no-fault compensation system for individuals who experience rare vaccine injuries. Instead of pursuing traditional tort lawsuits immediately, claims are first evaluated through a specialized court designed to compensate injuries more efficiently.

Since its creation, the program has awarded billions of dollars in compensation to individuals found to have vaccine-related injuries.

In other words, the program does not eliminate compensation, it changes the mechanism for addressing rare adverse events while maintaining a stable vaccine supply. Reducing this complex legal framework to “you can’t sue vaccine companies” is a simplification that obscures the historical reasons the system exists.

Claim #3: “Vaccines Were Never Tested Against Placebos”

Another widely circulated claim in the podcast is that routine childhood vaccines were never tested against placebo.

This claim relies on a misunderstanding of how clinical trials are designed.

Many vaccines are tested using randomized controlled trials, but the comparator is not always an inert saline placebo. Sometimes researchers use an active comparator, such as an existing vaccine or a formulation containing the same adjuvant.

Why?

Because once an effective vaccine exists, it may be unethical to leave participants unprotected in a placebo group. Clinical research ethics require balancing scientific rigor with participant safety. This approach is not unique to vaccines. Many areas of medicine rely on active comparators once effective treatments already exist. The absence of a saline placebo does not mean vaccines were never tested or evaluated. It reflects the ethical standards governing modern clinical research.

Claim #4: “Measles Was Harmless”

The conversation also revisits a familiar claim: measles was declining before vaccination and therefore the vaccine made little difference.

This argument hinges on a statistical misunderstanding.

Before the measles vaccine was introduced in 1963, the United States saw approximately three to four million infections each year. While most children recovered, measles caused tens of thousands of hospitalizations annually, along with hundreds of deaths and cases of brain inflammation.

Improvements in nutrition and medical care did reduce the probability of death once someone became infected. However, vaccines changed something far more important: the number of infections themselves.

After widespread vaccination, measles cases plummeted. By 2000, measles transmission had been declared eliminated in the United States. Reducing the number of infections is fundamentally different from reducing the severity of infections after they occur.

Vaccination achieved both.

Claim #5: The “Brady Bunch Measles Episode”

Perhaps the most unusual moment in the conversation occurs when Rogan and Siri reference a 1969 episode of The Brady Bunch in which several characters develop measles.

In the episode, the children lie in bed with spots and joke that measles is a convenient illness to have during a week without school. The story is played for laughs.

The clip is often circulated online as proof that measles was once considered harmless.

However, sitcoms are not public health data.

Television writers in the 1960s were not producing epidemiologic analyses. They were writing family comedies designed to entertain audiences. Childhood illnesses were often portrayed casually because they were common experiences for families at the time.

Yet the broader public health record tells a different story. Before vaccination, measles infected millions of Americans each year and caused thousands of severe complications.

The Brady Bunch episode also aired six years after the measles vaccine had already been introduced, during a period when vaccination rates were still rising.

What the episode reflects is cultural nostalgia, not medical reality.

Claim #6: “Measles Strengthens the Immune System”

Some discussions around measles go even further, suggesting that infection may be beneficial.

Modern immunology suggests the opposite.

Measles infection can cause what researchers call immune amnesia. The virus damages immune memory cells, erasing parts of the immune system’s existing defenses. After infection, individuals can become more susceptible to other diseases for months or even years.

Vaccination prevents this immune system reset. Rather than strengthening immunity, measles can temporarily weaken it.

The Bigger Pattern

Taken together, the claims in the Rogan–Siri conversation follow a familiar pattern.

First, legitimate historical facts are introduced: pharmaceutical companies have faced lawsuits, measles deaths declined before vaccines, and childhood illnesses were once common.

Then those facts are reframed to imply a much larger conclusion that vaccines are unnecessary, unsafe, or part of a broader deception. However, when examined closely, the conclusions do not follow from the premises.

Understanding this pattern is important, because misinformation rarely relies on entirely false statements. Instead, it often uses selective truths presented without context.

Context is what turns isolated facts into understanding.

Why This Matters

Public trust in medicine has been strained in recent years. The COVID-19 pandemic, changing guidelines, and widespread misinformation have all contributed to confusion and skepticism.

Healthy skepticism is not a problem. In fact, scientific progress depends on questioning assumptions and examining evidence, but skepticism requires standards.

Claims about vaccines should be evaluated the same way we evaluate any other medical intervention: through careful analysis of evidence, population data, and the balance of risks and benefits.

When a sitcom episode becomes evidence and epidemiology becomes optional, we’ve drifted far from that standard.

Science is not a religion. It is a method that is a slow, imperfect process of testing ideas against reality, and when it comes to vaccines, that process has produced one of the most successful public health interventions in human history.

Share

Food allergies have changed the way we raise kids.

Over the last 25 years, food allergy moved from rare diagnosis to daily reality. Classrooms have peanut-free tables. Parents carry epinephrine auto-injectors everywhere. Families read every food label twice. What once felt unusual is now routine.

At a recent FDA roundtable on food allergy, leading researchers, clinicians, patient advocates, and regulators gathered to discuss a central question: Why have food allergies increased and what should we be doing about it?

The answers were nuanced, but a few themes were clear:

1. Early prevention works.

In the early 2000s, parents were told to delay introducing peanut and other allergenic foods. That guidance has changed.

Landmark research like the LEAP trial demonstrated that introducing peanut in infancy, especially in infants at higher risk due to eczema or egg allergy, significantly reduces the risk of developing peanut allergy later. Follow-up studies suggest that early, regular consumption can lead to long-lasting protection.

There is now strong evidence for early peanut and good evidence emerging for egg. For other foods, data are less definitive but the overall message is consistent: once an infant is developmentally ready for solids (around 4–6 months), allergenic foods can be introduced in age-appropriate forms as part of the normal family diet.

The goal isn’t to medicalize every spoonful. It’s to normalize exposure during a window when the immune system is most adaptable.

One of the practical concerns raised during the panel is implementation. Current labeling language and cautious wording may unintentionally delay exposure past the ideal window. That delay can matter. Prevention works best when it’s simple and accessible.

2. Diagnosis requires context, not just testing.

Another important reminder from the panel: food allergy is diagnosed by a clinical reaction to ingestion, not by a positive blood test alone.

IgE testing and skin testing can support a diagnosis, but false positives are common when tests are used in isolation. We see this in clinic all the time: a concerning lab result without a real-world reaction. The gold standard remains careful clinical history and, when appropriate, a supervised oral food challenge.

Overdiagnosis creates unnecessary fear and restriction. Under diagnosis creates risk. Precision matters.

3. Treatment options are evolving, especially when started early.

We are in a new era of food allergy therapeutics.

Allergen-specific immunotherapies such as oral (OIT), sublingual (SLIT), and epicutaneous (patch-based) aim to retrain the immune system by gradually exposing it to the allergen. These approaches don’t simply suppress symptoms; they attempt to modify the immune response. Outcomes are particularly promising when therapy is started in toddlers, whose immune systems are more flexible.

Biologic therapies like omalizumab represent another strategy. Rather than targeting a specific food, they reduce IgE-mediated reactions more broadly and can help prevent severe reactions from accidental exposures. These treatments are not cures and require ongoing therapy, but they expand our safety net.

The regulatory discussion at the panel underscored the careful balance required. Trials must demonstrate meaningful benefit while maintaining safety, especially in children. There was thoughtful discussion about how to streamline development without compromising standards.

The encouraging takeaway: the field is moving forward, and regulators are actively engaged.

4. Eczema, the skin barrier, and unanswered questions

One of the strongest early-life predictors of food allergy remains eczema. Disrupted skin barrier function may allow sensitization before oral tolerance develops. Ongoing studies are examining whether aggressive early eczema treatment or targeted biologic therapies could reduce food allergy development in high-risk infants.

Beyond that lies a larger conversation: the microbiome, antibiotic exposure, C-section rates, breastfeeding patterns, environmental change. These are active research areas that are important hypotheses, not settled conclusions. However, they reflect a broader shift in thinking. We are no longer only reacting to allergy. We are asking how to prevent it upstream.

Earlier is better.

If there was one unifying theme across the panel, it was this: timing matters.

Early exposure can reduce risk. Early diagnosis can prevent unnecessary avoidance. Early treatment may improve long-term outcomes.

That shift — from avoidance and fear toward prevention and structured intervention — represents real progress.

This conversation is exactly why I wrote All About Allergies.

Families are overwhelmed. The science has evolved. Messaging has changed. Somewhere between headlines and shifting guidelines are parents trying to make safe, rational decisions for their kids. My goal with the book was to explain how the immune system actually works, clarify the evidence around food allergy prevention and treatment, and give families understanding instead of anxiety.

If you’ve already ordered the book, thank you so much! Truly, the support during launch has been incredible, and it means more than you know. If you’ve read it and found it helpful, leaving a review (on Amazon, Goodreads, or wherever you purchased it) makes a real difference in helping other families find it. Reviews are how books reach the people who need them.

Food allergy science doesn’t need panic.

It needs clarity, prevention, and steady progress, and for the first time in a long time, we are moving in that direction.

Order All About Allergies Here!

Share

The snow melts. The sun sticks around a little longer. We open the windows, and then my clinic fills up.

“Dr. Rubin, I think I’ve had a cold for three weeks.”
“My eyes won’t stop itching.”
“Why do I feel exhausted all the time?”
“Is this mold? Is this infection? Is this something worse?”

It’s not necessarily a cold.

It’s possibly tree pollen.

And in Chicago and across much of the U.S., it’s coming soon.

🌲 When Does Spring Allergy Season Start?

Here in the Midwest, tree pollen typically begins to rise in March, peaks in April and May, and can linger into early June depending on weather patterns.

Common culprits include:

• Oak

• Maple

• Birch

• Elm

• Cottonwood

Warm winters can shift timing. A sudden temperature swing can trigger intense bursts of pollen release. What about windy days? They’re basically pollen delivery systems.

If you have seasonal allergies, waiting until symptoms hit is already too late.

🤧 Why Allergy Symptoms Feel So Miserable

Allergies aren’t caused by pollen itself damaging you.

They’re caused by your immune system reacting to pollen as if it’s dangerous.

When someone with allergic rhinitis inhales tree pollen, their immune system produces IgE antibodies. Those antibodies trigger mast cells to release histamine and other inflammatory mediators.

That leads to:

• Runny or stuffy nose

• Itchy, watery eyes

• Sneezing

• Postnasal drip

• Fatigue

• Brain fog

It’s not infection. It’s inflammation.

Fortunately, inflammation can be treated, but it needs the right strategy.

🛑 The 5 Biggest Mistakes I See Every Spring

1. Starting medications after symptoms begin.
   Many allergy medications work best when started 1–2 weeks before pollen peaks.

2. Relying only on oral antihistamines.
   They help itching and sneezing but they don’t control inflammation as effectively as nasal steroid sprays.

3. Not using nasal sprays correctly.
   Aim slightly outward toward the ear, not straight up. Do not snort the spray. “If you taste it, then you waste it!”

4. Ignoring environmental control.
   Windows open at night + high pollen count = unnecessary suffering.

5. Assuming “it’s just allergies” when symptoms are severe.
   Uncontrolled allergic inflammation can worsen asthma and sleep.

🌿 What You Can Do Now

If you know spring hits you every year:

• Start a daily nasal steroid spray (if appropriate for you) before peak pollen.

• Check pollen counts regularly.

• Shower and change clothes after outdoor exposure.

• Use HEPA filtration indoors.

• Keep bedroom windows closed during high pollen days.

If symptoms are persistent year after year, consider seeing an allergist. Immunotherapy can change the trajectory of allergic disease, not just mask it.

Why I Wrote a Book About This

For years, I’ve watched people struggle through allergy seasons that could have been controlled, and I realized something:

Most people were never actually taught how the immune system works.

They were told what to take, but not why.

That’s exactly why I wrote All About Allergies, which officially launches tomorrow.

This book isn’t just about sneezing.

It’s about:

• How the immune system decides what’s dangerous

• Why some people develop asthma or food allergies

• How treatments like immunotherapy actually retrain the immune system

• What’s myth and what’s real

• How to advocate for yourself and your family

I wanted to create something that empowers people long before they’re sitting in an exam room frustrated. Because knowledge reduces fear, and understanding reduces suffering.

🌼 Spring Is Inevitable. Suffering Isn’t.

Tree pollen will arrive whether we prepare or not.

However, the difference between a miserable season and a manageable one often comes down to timing and information.

If allergies affect you, your child, or someone you love, I hope this season feels different.

And if you want to go deeper into how your immune system works in a way that’s clear, evidence-based, and actually readable, then my book officially launches tomorrow.

Thank you to everyone who has pre-ordered, shared, posted, messaged, and supported this journey. It truly means more than you know.

Let’s make this the year people breathe easier.

Preorder ALL ABOUT ALLERGIES in the US

Preorder ALL ABOUT ALLERGIES in the UK

If you preorder, you also get a digital mini cookbookthat is allergy friendly written by my wife and me. Today is the last day to get this free resource!

Share

Tomorrow is the final day to order a signed edition of my upcoming book, All About Allergies: Everything You Need to Know About Asthma, Food Allergies, Hay Fever, and More, through Anderson’s Bookshop. After tomorrow, signed copies will no longer be available through the store.

There’s something especially meaningful about partnering with a local independent bookstore in my own Chicago-area community, which is the store that I went to get books when I was a child. Independent bookstores do more than sell books, they support authors, host conversations, and help bring thoughtful, evidence-based work into the hands of readers who need it most. Choosing to order through Anderson’s not only gets you a signed edition, but it also supports a small business that has been an incredible partner in this journey.

All About Allergies is the book I’ve always wished my patients and families could take home from the exam room. It’s grounded in science but written in an approachable, conversational way, which is the way I speak to families every day. The book walks through asthma, food allergies, eczema, allergic rhinitis (i.e. hay fever), medication reactions, immunotherapy, and how the immune system actually works, using analogies and explanations that make complex concepts understandable without oversimplifying them. At its core, it’s about helping people feel informed rather than overwhelmed.

If you’ve been meaning to preorder for yourself, your family, your patients, or a friend who wants clear answers about allergies, then this is your reminder. Signed copies through Anderson’s close tomorrow.

You can order here.

I will also make an appearance there on February 24 when the book launches! Tickets can be ordered here.

Thank you to everyone who has already preordered, shared the book, and supported this mission to elevate thoughtful, science-based conversations about health. I’m deeply grateful.

Share

The Senate HELP Committee’s recent hearing produced a moment that deserves far more scrutiny than it’s received. Under questioning about vaccines and autism, Jay Bhattacharya, the director of the National Institutes of Health, was asked a direct yes-or-no question: Do vaccines cause autism? His response was telling. “I have not seen a study that suggests any single vaccine causes autism.” The answer sounded reassuring at first glance. However, the wording matters, and in this case, it matters a great deal.

The scientific consensus on this question is not ambiguous. Vaccines do not cause autism. This conclusion is not based on a single study or one vaccine product, but on decades of epidemiologic research involving millions of children, examining individual vaccines, combined schedules, and vaccine components. Major medical organizations and global public health bodies have repeatedly reviewed the evidence and reached the same conclusion. There is no credible causal link between vaccination and autism spectrum disorder. When a senior federal science official answers a direct question about that reality with careful narrowing language, it’s reasonable to ask why.

The phrase “any single vaccine” does significant rhetorical work. It allows the speaker to technically align with the evidence while leaving open the implication that something else such as combinations, schedules, cumulative exposure, or unidentified mechanisms might still be responsible. Those hypotheses are not new. They have been studied extensively, and they have failed to demonstrate a causal relationship. By restricting his answer to “any single vaccine,” Bhattacharya avoided stating the broader conclusion that the evidence actually supports. That’s not scientific precision; it’s hedging.

This matters because the question was not academic. It came in the context of a broader discussion about declining public trust in medicine and public health institutions. Bhattacharya cited survey data showing that trust in physicians has fallen sharply since the start of the COVID-19 pandemic, dropping to roughly 40 percent by early 2024. That decline is real, but the existence of mistrust does not validate the claims driving it. If anything, the data show that distrust correlates with poorer health outcomes and lower vaccine uptake. Rebuilding trust requires clarity, not carefully constructed ambiguity.

The political context makes the hedging even more consequential. Bhattacharya now serves under an administration in which Robert F Kennedy Jr, the Secretary of Health and Human Services, has repeatedly questioned vaccine safety and suggested links to autism, despite the lack of evidence. Recent controversies surrounding federal health agency messaging including softened or altered language about vaccines and autism have further confused the public. Against that backdrop, the NIH director’s words carry enormous weight. When the nation’s top biomedical research official does not plainly affirm a settled scientific conclusion, it leaves room for doubt where none is warranted.

It’s important to be precise here. Bhattacharya did not endorse the claim that vaccines cause autism. He did not cite discredited studies or repeat outright falsehoods. However, public health communication is not graded on technical plausibility alone. It is judged by what people hear and how messages land in a climate already saturated with misinformation. In that environment, refusing to say “vaccines do not cause autism” is not a neutral act. It reinforces uncertainty, even if unintentionally.

If restoring trust in medicine is truly the goal, then leaders must be willing to state plainly what the evidence shows, even when that clarity is politically inconvenient. Autism is real. Adverse Vaccine reactions are possible, but a causal link between vaccines and autism is not. Conflating uncertainty about trust with uncertainty about evidence only deepens the very mistrust officials claim to be concerned about.

The takeaway from that exchange isn’t that science is unclear or evolving on this question. It’s that political caution is now shaping how scientific truths are voiced, and when that happens, the public doesn’t hear nuance, people hear doubt.

Share

Medicine is everywhere right now, and somehow, understanding it has never felt harder.

Health claims go viral before facts can catch up. Nuance gets flattened. Fear spreads faster than evidence. Credentials get weaponized, while context quietly disappears.

That’s why we launched From Bench to Bedside.

Not to be louder.
Not to win arguments.
But to slow things down and explain what’s actually happening.

Who We Are (and Why We’re Doing This Together)

This podcast is hosted by the two of us—husband and wife—coming at medicine from different, but deeply connected, angles.

My wife, Melanie Matheu, is a PhD-trained immunologist, inventor, and entrepreneur. Her work lives at the bench and beyond: basic science, immune mechanisms, translational research, and building ideas into real-world solutions. She is the “Bench.”

I’m a practicing physician, double board-certified in pediatrics and allergy/immunology. My work lives at the bedside: clinic visits, real patients, real decisions, and the very human consequences of misinformation. I am the “Bedside.”

Between us, we span the full arc of modern medicine, from molecules and mechanisms to exam rooms and public policy, and we’ve seen the same problem from both sides.

What “Bench to Bedside” Really Means

In medicine, bench to bedside describes the long, imperfect journey from basic science—cells, signaling pathways, immunology, data—to real people sitting in exam rooms, emergency departments, and hospital beds.

That journey is rarely linear. It’s full of uncertainty, tradeoffs, evolving evidence, and judgment calls.

Online, that complexity is often erased.

Our goal with this podcast is to reconnect those dots:

• What the science actually shows

• How it gets translated (or distorted) on the way to the public

• Where certainty ends and clinical judgment begins

• What all of this means for patients and families trying to make decisions

No hype. No fear-bait. No pretending medicine is simple.

Why This Podcast, Why Now

We’re living through a moment where:

• Misinformation is rewarded by algorithms

• Partial truths are framed as “hidden knowledge”

• Distrust is profitable

• And “do your own research” often means being funneled toward the most extreme take

We see the downstream effects every day in clinic, in research spaces, and in conversations with people who are scared, confused, or understandably skeptical.

This podcast is our response to that moment.

Not to shame.
Not to lecture.
But to explain.

To say: You’re not wrong for feeling overwhelmed. Medicine is complicated. Let’s walk through it together.

What You’ll Hear on the Podcast

Each episode tackles real-world health topics with context and evidence, including:

• Vaccine misinformation and how it spreads

• Infectious disease outbreaks (measles, flu, COVID, RSV)

• Public health decisions and how they’re actually made

• What studies do—and don’t—prove

• Where uncertainty is real, and where false balance is misleading

Sometimes it’s calm and explanatory.
Sometimes it’s rapid-fire debunking.
Sometimes it’s uncomfortable.

However, it’s always grounded in science and lived experience—both at the bench and at the bedside.

Who This Is For

This podcast is for:

• People who want to understand health news without being manipulated

• Clinicians who are tired of seeing nuance stripped away

• Parents trying to make sense of conflicting advice

• Anyone who values evidence and humility

You don’t need a medical background. You just need curiosity—and a willingness to sit with complexity.

Where to Listen

🎧 From Bench to Bedside is available on YouTube and all major podcast platforms, with full show notes and sources so you can dig deeper if you want.

If you care about how science becomes medicine, and how medicine affects real people, we’d love to have you listening.

Because clarity is an antidote to fear, and context still matters.

Amazon Music

Spotify

Apple Podcast

Share

When the chair of the Advisory Committee on Immunization Practices (ACIP) speaks, the stakes are enormous. ACIP recommendations don’t just shape clinical guidance; they shape trust, vaccine uptake, school policies, and ultimately whether preventable diseases return. That is why the recent podcast interview with Dr. Kirk Milhoan, the current chair of ACIP who is a pediatric cardiologist, should deeply concern anyone who cares about children’s health.

This concern is not about politics, ideology, or personal faith. It is about method, evidence, and rhetoric. Throughout the interview, Dr. Milhoan repeatedly undermines foundational principles of medical science, reframes risk in misleading ways, and casts doubt on the safety and value of routine childhood vaccines using language that departs sharply from established evidence. When these claims come from someone in his position, the downstream consequences are real.

Redefining science in a way that abandons rigor

One of the most revealing moments in the interview comes when Dr. Milhoan is challenged on whether he is relying on established scientific evidence or personal impressions. His response is stark:

“But that’s not science. Science is what I observe.”

This statement is not a semantic quibble; it represents a fundamental misunderstanding of how biomedical science works. Observation is the starting point of science, not its conclusion. Modern medicine depends on systematic data collection, controlled trials, replication, population-level inference, and methods explicitly designed to reduce individual bias. Elevating personal observation to the level of scientific authority is precisely why evidence-based frameworks exist, which is to protect patients from the limitations of individual experience.

Equally concerning is his rejection of the concept of scientific proof:

“When people use the word ‘proven,’ it’s a contradiction to the word science.”

This rhetorical move is common in misinformation spaces. Science does not claim absolute certainty; it relies on converging evidence, consistency across populations, biological plausibility, and reproducibility. Vaccines like MMR are not “proven” in a philosophical sense; they are supported by decades of high-quality epidemiologic, clinical, and real-world data. Rejecting the word “proven” becomes a way to suggest perpetual uncertainty even where consensus is overwhelming.

Calling vaccine safety an “emotional” concept

Perhaps the most destabilizing claim in the interview is Dr. Milhoan’s insistence that safety is not a scientific concept at all:

“I don’t like the word safety. Safety is not a scientific word. Safety is an emotional response to risk.”

In medicine, safety is a rigorously quantified concept. It is measured through adverse-event rates, severity classification, confidence intervals, post-marketing surveillance, and comparative risk assessment. Calling safety “emotional” reframes empirically measured risk as subjective fear, subtly delegitimizing the massive body of vaccine safety science that already exists.

This framing allows Dr. Milhoan to later assert without evidence that vaccines have largely escaped proper safety scrutiny:

“No, they haven’t been [appropriately studied for safety]. They’ve been mostly studied for efficacy.”

This statement is simply false. Vaccine safety evaluation occurs before licensure and continues for years afterward through multiple independent systems, including passive signal detection and active surveillance. One can reasonably argue about the strengths or limitations of specific systems but claiming that vaccines are mostly not studied for safety misrepresents decades of work and invites unwarranted fear.

Downplaying measles by anchoring it to the past

Measles serves as a litmus test for whether someone understands the difference between historical context and current biological reality. Dr. Milhoan repeatedly frames measles as a disease whose risks largely belonged to an earlier era:

“Many of those risks… were in the 1960s. We take care of children much differently now.”

This argument is misleading. Better supportive care reduces mortality, but it does not eliminate the risk of severe complications like pneumonia, encephalitis, or death. Measles remains a highly contagious airborne virus, and modern outbreaks repeatedly demonstrate that it causes serious harm in unvaccinated populations today, not just in historical archives. The ongoing measles outbreak in the United States that started in January 2025 has resulted in ongoing transmission and 3 deaths (2 children and 1 adult). There was an additional measles death in a child who was infected years earlier and developed subacute sclerosing panencephalitis (SSPE), a devastating neurodegenerative disease.

When pressed directly on whether vaccination is the best way to prevent measles, Dr. Milhoan offers a notably qualified response:

“I think it’s very helpful… pretty damn close.”

For the chair of ACIP, hesitation on this point matters. The evidence supporting measles vaccination as the most effective prevention strategy is among the strongest in all of infectious disease medicine. Public ambivalence from leadership erodes clarity precisely when outbreaks are resurging.

Inflating vaccine risk while minimizing disease risk

Throughout the interview, Dr. Milhoan repeatedly emphasizes rare vaccine adverse events while downplaying or relativizing the harms of disease. This imbalance is subtle but powerful. At one point, he frames vaccine injury and disease harm as morally equivalent scenarios:

“There could be unintended harm if we give it, and unintended harm if we don’t.”

While technically true, this framing collapses proportionality. Medicine is not about whether risk exists, it is about how much risk exists and compared to what. By that logic, we would treat the rare risk of an allergic reaction to antibiotics as equivalent to the risk of untreated bacterial sepsis. Vaccines are recommended because the risk of serious adverse events is orders of magnitude lower than the risk of harm from the diseases they prevent. Presenting these risks as roughly symmetrical misleads parents who lack the tools to contextualize epidemiologic scale.

Unsupported claims about outbreaks and vaccination failure

One particularly alarming moment comes when Dr. Milhoan asserts:

“We have a major pertussis outbreak in Texas and 100 percent of the people who got pertussis were vaccinated.”

This claim has not been substantiated by publicly available surveillance data and contradicts how pertussis epidemiology is typically reported. Even when outbreaks occur in highly vaccinated communities, that does not imply vaccine failure; it reflects waning immunity, incomplete coverage, or clustering among under vaccinated groups. Even so, vaccinating against pertussis also decreases the risk of serious disease. Statements like this, delivered without evidence, risk convincing the public that vaccines are ineffective when the reality is more nuanced.

Elevating autonomy while sidelining public health

Dr. Milhoan repeatedly states that ACIP is shifting its orientation:

“We are returning individual autonomy to the first order. Not public health.”

This is a profound redefinition of ACIP’s mission. ACIP has always considered individual risk while offering population-level guidance designed to protect communities, especially those who cannot be vaccinated due to medical conditions. Framing public health as secondary reframes collective protection as coercive rather than ethical.

His opposition to school vaccine requirements follows naturally from this view:

“Do we need to mandate these vaccines to go to kindergarten? I don’t think so.”

This position ignores the historical role school-based requirements have played in preventing outbreaks and protecting vulnerable children. Mandates are not about forcing uniformity; they are about preventing predictable harm when voluntary uptake falls below protective thresholds.

The danger is not his personal doubt—it’s his platform

Dr. Milhoan frequently emphasizes humility and openness to being wrong. That posture, by itself, is admirable. The problem is not uncertainty; the problem is where that uncertainty is expressed and how it is framed. When the chair of ACIP publicly suggests that vaccine safety is poorly understood, that measles risks are largely historical, and that scientific consensus is merely institutional bias, parents do not hear nuance, they hear permission to delay, refuse, or distrust.

The most troubling aspect of the interview is not any single claim. It is the cumulative effect: redefining science, recasting safety as emotion, inflating rare risks, and weakening clear endorsements of routine vaccines, all while occupying a position designed to stabilize trust.

Parents deserve transparent information. Clinicians deserve guidance grounded in evidence. Children deserve protection from diseases we already know how to prevent. Leadership that equivocates on these fundamentals does not merely invite debate; it invites resurgence of harm we have spent generations working to prevent.

This interview should not be ignored. It should be examined carefully, quoted accurately, and responded to clearly because when trust erodes at the top, the fallout is measured not in headlines, but in hospitalizations, outbreaks, and lives that never needed to be lost.

Share